Andrea Ratfield v. United States Drug Testing Laboratories, Inc.

140 F.4th 849
CourtCourt of Appeals for the Seventh Circuit
DecidedJune 13, 2025
Docket24-1858
StatusPublished
Cited by2 cases

This text of 140 F.4th 849 (Andrea Ratfield v. United States Drug Testing Laboratories, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Andrea Ratfield v. United States Drug Testing Laboratories, Inc., 140 F.4th 849 (7th Cir. 2025).

Opinion

In the

United States Court of Appeals For the Seventh Circuit ____________________ No. 24-1858 ANDREA RATFIELD, et al.,

Plaintiffs-Appellants,

v.

UNITED STATES DRUG TESTING LABORATORIES, INC., et al., Defendants-Appellees. ____________________

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 1:23-cv-15063 — Robert W. Gettleman, Judge. ____________________

ARGUED JANUARY 16, 2025 — DECIDED JUNE 13, 2025 ____________________

Before SCUDDER, KIRSCH, and LEE, Circuit Judges. LEE, Circuit Judge. Plaintiffs, comprised of Andrea Ratfield, ten other pilots, a physician, a nurse, and an attorney, were all required to undergo alcohol testing to maintain their employ- ment and professional licenses. Here, the testing came in the form of a dried blood spot test developed by United States Drug Testing Laboratories, Inc. (USDTL). According to USDTL, its test (which we will refer to as DBS) is designed to 2 No. 24-1858

detect phosphatidylethanol (PEth), a biomarker of alcohol consumption. The DBS tests for Ratfield and the others indi- cated positive for PEth, presumably meaning that they had continued to consume alcohol even while participating in their treatment programs. These positive tests, Plaintiffs al- lege, resulted in significant professional harm. Asserting that the DBS tests were not as reliable as USDTL touted, the fourteen individuals sued USDTL and two of its officers (collectively, the USDTL Defendants) under the Rack- eteer Influenced and Corrupt Organizations Act, 18 U.S.C. § 1962 (RICO), and state law. They also named as defendants Choice Labs Services (CLS), the company that provided the DBS tests to the test administrators, and its owners (collec- tively, the CLS Defendants). The district court dismissed the RICO claims under Federal Rule of Civil Procedure 12(b)(6) and denied supplemental jurisdiction as to the state law claims. We affirm. I The crux of Plaintiffs’ RICO claims is their allegation that USDTL marketed its DBS test as a reliable indicator of contin- uing alcohol use when, in fact, the company had failed to con- firm the test’s validity and reliability. Some background into the various players will be helpful. 1 USDTL is a business-to-business specimen testing labora- tory that developed the DBS test. Douglas Lewis is USDTL’s

1 The background facts are taken from the second amended com- plaint. On appeal, we treat the allegations as true and view them in the light most favorable to Plaintiffs. See Moranski v. Gen. Motors Corp., 433 F.3d 537, 539 (7th Cir. 2005). No. 24-1858 3

founder, president, and scientific director, and Joseph Jones is USDTL’s chief operating officer and executive vice president. The Centers for Medicare and Medicaid Services (CMS) is the federal agency that regulates all non-research laboratory testing on humans in accordance with the Clinical Laboratory Improvement Amendments, 42 U.S.C. § 263a, and its imple- menting regulations, 42 C.F.R. Part 493 (together, CLIA). The purpose of the CLIA is to ensure the accuracy and reliability of laboratory tests, and CLIA certification signifies that a la- boratory has met statutory and regulatory conditions. USDTL claims to be CLIA-certified and -compliant. Ratfield and the other pilots participated in the Human In- tervention Motivational Study (HIMS) program, a substance abuse treatment program that helps professional pilots return to cockpits after recovering from alcohol or other substance use disorders. HIMS requires pilots to submit to frequent drug or alcohol testing to rule out continued use. CLS is a Georgia-based company that performs drug test- ing and recovery monitoring services. It is owned by Lisa Michele and Robert Gable. HIMS used CLS to oversee the test- ing of program participants for alcohol consumption. And CLS directed the pilots to certain laboratories and instructed the laboratories to use USDTL’s DBS test for this purpose. 2 According to Plaintiffs, USDTL compensated CLS for

2 At one point in their second amended complaint, Plaintiffs allege that it was CMS that directed the pilots to certain laboratories for testing. But the remaining allegations demonstrate that this was a typographical error. 4 No. 24-1858

funneling individuals in occupational substance abuse treat- ment programs to these laboratories and for supplying the la- boratories with the DBS tests. 3 Plaintiffs initially filed suit in December 2022 against the USDTL Defendants in the Southern District of Florida, assert- ing claims for common law fraud and negligence. They later amended the complaint, claiming that the USDTL Defendants also violated RICO by committing mail and wire fraud. Spe- cifically, Plaintiffs alleged that the USDTL Defendants fraud- ulently misrepresented that their DBS test was accurate and reliable and reaped financial gains as a result. The district court dismissed the case without prejudice, concluding that the complaint had failed to adequately allege that the RICO enterprise had been sufficiently distinct from the corporate in- dividuals or that the USDTL Defendants had caused the pur- ported harm. As a result, Plaintiffs filed a second amended complaint, this time adding the CLS Defendants. The district court then transferred the case to the Northern District of Illinois pursuant to 28 U.S.C. § 1404(a), at which point Defendants filed a motion to dismiss the second amended complaint for failure to state a claim. The district court granted the motion and later denied Plaintiffs’ motion to alter or amend the judgment under Rules 59(e) and 60(b). This appeal followed.

3 Although their individual circumstances are not exactly clear, the other three Plaintiffs (a doctor, nurse, and attorney) also took USTDL’s DBS tests provided by CLS as a condition of maintaining their professional licenses and employment. The particular details are not relevant to this appeal. No. 24-1858 5

II We review de novo the district court’s order dismissing Plaintiffs’ complaint for failure to state a claim under Rule 12(b)(6). Abcarian v. McDonald, 617 F.3d 931, 933 (7th Cir. 2010). “When analyzing the sufficiency of a complaint, we ‘must construe it in the light most favorable to [Plaintiffs], ac- cept well-pleaded facts as true, and draw all inferences in [Plaintiffs’] favor.’” Yash Venture Holdings, LLC v. Moca Fin., Inc., 116 F.4th 651, 656 (7th Cir. 2024) (quoting Carlson v. CSX Transp., Inc., 758 F.3d 819, 826 (7th Cir. 2014)). The “complaint must ‘contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face.’” Flores v. City of S. Bend, 997 F.3d 725, 728–29 (7th Cir. 2021) (quoting Ash- croft v. Iqbal, 556 U.S. 662, 678 (2009)). Moreover, because Plaintiffs’ civil RICO claims sound in fraud, the circumstances must be described “with particularity” to satisfy Rule 9(b)’s heightened pleading requirement.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
140 F.4th 849, Counsel Stack Legal Research, https://law.counselstack.com/opinion/andrea-ratfield-v-united-states-drug-testing-laboratories-inc-ca7-2025.